Genome-wide Methylation and Gene Re-expression Analysis of Resectable Lung Tumor Tissue Pairs Obtained Pre- and Post-treatment With 5-Azacytidine and Entinostat

Trial Profile

Genome-wide Methylation and Gene Re-expression Analysis of Resectable Lung Tumor Tissue Pairs Obtained Pre- and Post-treatment With 5-Azacytidine and Entinostat

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs Azacitidine (Primary) ; Entinostat (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 17 May 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 03 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
    • 11 Feb 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top